As a possible S100A4-targeting therapeutic, niclosamide was first identified through a high-throughput screen with HCT116 human CRC cell line using a S100A4-promoter-driven luciferase reporter assay (125). This evidence concerns the gene S100A4 and colorectal carcinoma.